- Home
- BIIB vs TKO Comparison
BIIB vs TKO Comparison
Compare BIIB & TKO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TKO
- Stock Information
- Founded
- BIIB 1978
- TKO 1980
- Country
- BIIB United States
- TKO United States
- Employees
- BIIB N/A
- TKO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TKO
- Sector
- BIIB Health Care
- TKO
- Exchange
- BIIB Nasdaq
- TKO Nasdaq
- Market Cap
- BIIB 18.7B
- TKO 15.6B
- IPO Year
- BIIB 1991
- TKO N/A
- Fundamental
- Price
- BIIB $155.64
- TKO $180.98
- Analyst Decision
- BIIB Buy
- TKO Strong Buy
- Analyst Count
- BIIB 24
- TKO 17
- Target Price
- BIIB $174.62
- TKO $213.69
- AVG Volume (30 Days)
- BIIB 1.6M
- TKO 1.2M
- Earning Date
- BIIB 10-30-2025
- TKO 11-05-2025
- Dividend Yield
- BIIB N/A
- TKO 1.70%
- EPS Growth
- BIIB N/A
- TKO N/A
- EPS
- BIIB 10.97
- TKO 1.85
- Revenue
- BIIB $10,065,900,000.00
- TKO $2,545,175,000.00
- Revenue This Year
- BIIB $2.97
- TKO $69.02
- Revenue Next Year
- BIIB N/A
- TKO $27.62
- P/E Ratio
- BIIB $14.24
- TKO $96.59
- Revenue Growth
- BIIB 4.77
- TKO N/A
- 52 Week Low
- BIIB $110.04
- TKO $115.77
- 52 Week High
- BIIB $175.86
- TKO $212.49
- Technical
- Relative Strength Index (RSI)
- BIIB 62.21
- TKO 32.79
- Support Level
- BIIB $151.83
- TKO $177.41
- Resistance Level
- BIIB $157.79
- TKO $190.24
- Average True Range (ATR)
- BIIB 4.71
- TKO 4.11
- MACD
- BIIB 0.51
- TKO -0.53
- Stochastic Oscillator
- BIIB 91.06
- TKO 23.15
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.